Investment Rating - The report maintains a "Buy-A" investment rating for the company with a target price of 95.60 CNY per share over the next six months [5][6]. Core Insights - The company is expected to achieve significant growth in its financial performance, with projected revenues of 20.799 billion CNY and adjusted net profit of 6.315 billion CNY for the first half of 2025, representing year-on-year increases of 20.64% and 44.43% respectively [1][2]. - The expansion of the small molecule D&M pipeline is driving steady growth in this segment, with 203 new molecules added in Q1 2025 and successful FDA inspections of production facilities [3]. - The TIDES business is experiencing rapid growth, with a 105.5% year-on-year increase in orders and a significant expansion in production capacity from 32,000 liters in 2023 to 100,000 liters by the end of 2025 [4]. Financial Projections - The company’s projected net profits for 2025 to 2027 are 13.735 billion CNY, 13.872 billion CNY, and 16.210 billion CNY, reflecting year-on-year growth rates of 45.3%, 1.0%, and 16.9% respectively [5][11]. - The expected earnings per share (EPS) for 2025 is 4.78 CNY, with a price-to-earnings (PE) ratio of 20 times [5][11]. - The company’s total market capitalization is approximately 221.59 billion CNY, with a circulating market capitalization of about 191.73 billion CNY [6]. Stock Performance - The stock has shown strong relative performance, with a 1-month return of 15.5%, a 3-month return of 41.0%, and a 12-month return of 83.0% [9].

2025 年 07 月 14 日 建筑 建筑企业联合倡议反内卷，企业盈利有 望改善，建议关注低估值高股息标的 | 投资评级 | 领先大市-B | | --- | --- | | | 维持评级 | | 行业表现 | | | | | --- | --- | --- | --- | | 39% | 建筑 | 沪深300 | | | 29% | | | | | 19% | | | | | 9% | | | | | -1% | | | | | -11% | | | | | 2024-07 | 2024-11 | 2025-03 | 2025-07 | | 资料来源：Wind 资讯 | | | | | 升幅% | 1M | 3M | 12M | | 相对收益 | 0.8 | 2.0 | 4.7 | | 相对收益 | 0.8 | 2.0 | 4.7 | | --- | --- | --- | --- | | 绝对收益 | 3.9 | 9.1 | 20.5 | | | 董文静 | | 分析师 | SAC 执业证书编号：S1450522030004 dongwj@essence.com.cn 陈依凡 分析师 SAC 执业证书编 ...

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 49.70 CNY, maintaining the rating [4][8]. Core Views - The company is expected to achieve significant revenue growth, with projected revenues for H1 2025 between 358-398 million CNY, representing a year-on-year increase of 67.42%-86.02% [1]. - The company is expanding its new business segments, including smart equipment for household paper, industrial robots, and drones, which are anticipated to drive future growth [2][3]. - The company is actively increasing production capacity and expanding into overseas markets, particularly in Southeast Asia and the Middle East, to support its growing order book [2]. Summary by Sections Financial Performance - For H1 2025, the company expects a net profit of 68-73 million CNY, a year-on-year increase of 51.24%-61.66%, and a non-recurring net profit of 62-67 million CNY, growing by 93.83%-108.47% [1]. - In Q2 2025, the anticipated revenue is between 159-199 million CNY, with a year-on-year growth of 79.46%-124.35% [1]. Business Expansion - The household paper equipment segment is experiencing rapid growth, with Q1 2025 orders reaching 310 million CNY, and the company plans to launch new products in the second half of the year [2]. - The establishment of a 1.5 billion CNY smart manufacturing fund in collaboration with local governments aims to invest in high-end equipment manufacturing, which is expected to create new revenue streams [3]. Future Projections - Revenue forecasts for 2025-2027 are 1.264 billion CNY, 1.585 billion CNY, and 1.906 billion CNY, reflecting year-on-year growth rates of 191.02%, 25.32%, and 20.28% respectively [4][9]. - The company is focusing on enhancing its core competencies in equipment and materials, leveraging its established manufacturing capabilities to respond quickly to emerging market demands [3].

2025 年 07 月 13 日 银行：会跌倒么？ 本周上证指数涨 1.09%，创业板指涨 2.36%，恒生指数涨 0.93%，大盘股涨幅居前，本周全 A 日均交易额 14961 亿，环比上周有所上升。这点符合我们在上期周报《最佳的选择："创"》 的判断："大盘指数维持强势"，但眼下不急于对大盘指数"牛不牛"下判断（尤其是快牛）， "找准结构和方向"依然是最重要的。现阶段风险偏好抬升是定价核心矛盾，科技科创依然 是维持占优推荐，而相对低估值分位的大盘成长（创业板指）或将成为最为受益的方向。同 时，在上周周报中我们强调今年本轮 A 股大盘整体超预期偏强：即银行板块贡献了上半年绝 大多数的涨幅，上证指数从年初的 3347 点涨到最新 3510 点附近，银行对大盘贡献高达到 118.13 点。客观而言，只要银行维持上涨，那么"银行搭台、多方唱戏"将延续，大盘较难"二 次探底"。 本周五大盘指数出现冲高回落，对应银行板块发生下跌，市场生怕"银行跌倒"？目前银行 确实涨很久了，难免会有见顶回落的忧虑。我们认为现在没看到明确的理由，暂不是看空银 行的时候。目前，从估值提升的角度，资金对于银行的抱团大致接近 2020 年中 ...

Investment Rating - The report maintains an investment rating of "Leading the Market - A" [7] Core Insights - The real estate market is experiencing a significant decline in sales, with new home transactions in key cities dropping by 50.5% week-on-week, reaching a new low since the Chinese New Year [1][2] - The report suggests that the market is awaiting policy easing, with a focus on the upcoming Politburo meeting to determine the direction of new real estate policies [1] - Companies that may benefit from a turnaround include those in distress such as China Vanke and New Town Holdings, as well as leading firms maintaining land acquisition intensity like China Merchants Shekou, Greentown China, Poly Developments, and Binjiang Group [1] Sales Review (July 5-11) - Total new home transactions in 32 monitored cities amounted to 12,000 units, a 50.5% decrease from the previous week; cumulative transactions for 2025 reached 441,000 units, down 5.4% year-on-year [2][13] - First-tier cities saw transactions of 3,022 units, down 54.7% week-on-week, with a cumulative total of 126,000 units for 2025, reflecting a 6.2% year-on-year increase [2][14] - Second-tier cities recorded 7,192 units sold, a 52.5% decrease week-on-week, with a cumulative total of 264,000 units for 2025, down 9.8% year-on-year [2][14] - Third-tier cities had 1,287 units sold, an 8.9% decrease week-on-week, with a cumulative total of 51,000 units for 2025, down 6.3% year-on-year [2][14] Land Supply (June 30 - July 6) - The planned land supply for residential land in 100 cities was 5.51 million square meters, with a cumulative supply of 11.368 million square meters for 2025, down 12.9% year-on-year [3][22] - The average listing price for land in 100 cities was 4,717 yuan per square meter, with a recent four-week average of 4,934 yuan per square meter, reflecting a 9.5% decrease week-on-week but a 3.4% year-on-year increase [3][24] Land Transactions (June 30 - July 6) - The total area of residential land transactions in 100 cities was 4.95 million square meters, with a cumulative total of 10.005 million square meters for 2025, up 6.7% year-on-year [4][45] - The average transaction price for residential land was 5,708 yuan per square meter, down 33.7% week-on-week but up 50.8% year-on-year, with an overall premium rate of 5.8% [4][47]

Investment Rating - The report maintains an investment rating of "Leading the Market - A" [9] Core Insights - The report highlights that several newly included innovative drugs in the medical insurance directory are rapidly entering hospitals, with significant growth in the number of drugs entering hospitals by the end of May 2025 compared to April 2025 [2][22] - The report notes that the new drug sector has shown a strong performance, with notable increases in stock prices for companies such as Beihai Kangcheng (114.5%), Frontier Biotech (41.4%), and Junsheng Tai (29.4%) during the week of July 7 to July 13, 2025 [1][18] Summary by Sections Weekly New Drug Market Review - From July 7 to July 13, 2025, the top five companies in the new drug sector by stock price increase were Beihai Kangcheng (114.5%), Frontier Biotech (41.4%), Junsheng Tai (29.4%), Kaituo Pharmaceutical (20.7%), and Yongtai Biotech (20.1%) [1][18] - The top five companies by stock price decrease were Yiming Anke (-19.4%), Shenzhou Cell (-13.4%), Ascentage Pharma (-10.0%), Lepu Biotech (-8.9%), and Rongchang Biotech (-8.8%) [1][18] Key Analysis of the New Drug Industry - The National Medical Insurance Administration updated the hospital admission data for innovative drugs included in the medical insurance directory as of the end of May 2025, indicating rapid hospital admissions for several newly included domestic innovative drugs [2][22] - Notable drugs with fast admission growth included Kangfang Biotech's Cardunilumab and Ivorisumab, Shanghai Yizhong's Paclitaxel Micelle, and Zecjin Pharmaceutical's Recombinant Human Thrombin [2][22] New Drug Approval and Acceptance Status - Four new drug or new indication applications were approved this week, including Ascentage Pharma's Lisatoclax tablets and Zhejiang Tianyuan's quadrivalent influenza virus split vaccine [26][27] - Ten new drug applications were accepted, including Dali Yingjie’s Docetaxel Injection and Zhaoke Pharmaceutical's Atropine Sulfate Eye Drops [26][28] Clinical Application Approval and Acceptance Status - This week, 43 new drug clinical applications were approved, and 20 new drug clinical applications were accepted [4][28]

Investment Rating - The report maintains an investment rating of "Outperform" [5] Core Insights - The electronic sector has shown a weekly increase of 0.45%, ranking 26th out of 31 sectors, with the electronic index PE at 52.93 times [3][28][37] - The report highlights the launch of Nvidia's GB300 server and the Grok4 AI model by Tesla, indicating significant advancements in AI and computing capabilities [1][2] Industry Performance - The Shanghai Composite Index rose by 1.09%, the Shenzhen Component Index increased by 1.78%, and the CSI 300 Index went up by 0.82% during the week [28] - The electronic sector's performance includes a 1.12% increase in the Shenwan electronic sector index [3] Sector Data Tracking - The semiconductor sector's PE is reported at 81.87 times, with a 55.90% percentile ranking, while the consumer electronics sector stands at 28.69 times with an 11.74% percentile ranking [41] - The report notes that the SiC power device market is expected to grow at a CAGR of 20% from 2024 to 2030, reaching $10.3 billion [18] Weekly Market Review - The electronic sector's top gainers include C Yitang (+147.81%), C Tongyu (+141.71%), and Xinya Electronics (+31.85%), while the biggest losers were Rui Lian New Materials (-15.98%), Zhongjing Electronics (-13.78%), and Baoming Technology (-13.64%) [36]

Quantitative Models and Construction Methods 1. Model Name: Galaxy CSI 300 Enhanced Index Fund (007275.OF) - **Model Construction Idea**: The fund aims to track the CSI 300 Index effectively while employing quantitative methods for active portfolio management and risk control to achieve performance exceeding the benchmark index and generate long-term asset appreciation [2][38][60] - **Model Construction Process**: - The fund uses multi-factor stock selection, index replication, and event-driven strategies to enhance returns while optimizing the portfolio and strictly controlling risks [60] - The fund aims to control the absolute value of the daily tracking deviation between the net value growth rate and the performance benchmark within 0.5% and the annual tracking error within 7.75% [38] - **Model Evaluation**: The model demonstrates strong performance in generating excess returns, maintaining low tracking error, and effectively controlling risks [38][42][44] --- Model Backtesting Results 1. Galaxy CSI 300 Enhanced Index Fund - **Annualized Excess Return**: 6.49% since inception [39][42] - **Annual Excess Returns (2020-2025)**: 13.24% (2020), 11.06% (2021), 4.17% (2022), 2.83% (2023), 4.49% (2024), 3.27% (2025 YTD) [43] - **Maximum Drawdown (2020-2025)**: -15.78% (2020), -12.43% (2021), -24.09% (2022), -17.98% (2023), -10.89% (2024), -10.00% (2025 YTD) [44] - **Sharpe Ratio (2020-2025)**: 1.50 (2020), 0.33 (2021), -1.27 (2022), -0.82 (2023), 0.94 (2024), 1.60 (2025 YTD) [44] - **Information Ratio (2020-2025)**: 4.01 (2020), 3.50 (2021), 1.72 (2022), 1.25 (2023), 1.48 (2024), 3.75 (2025 YTD) [44] - **Tracking Error**: Annual tracking error averaged 2.68% from 2020, with a maximum of 3.38%, meeting the target of staying below 7.75% [45] - **2025 YTD Information Ratio**: 3.98, ranking 5th among CSI 300 Enhanced Index Funds [45][47] --- Quantitative Factors and Construction Methods 1. Factor Name: Multi-Factor Stock Selection - **Factor Construction Idea**: The fund employs a multi-factor model to identify stocks with high potential for excess returns based on various quantitative metrics [60] - **Factor Construction Process**: - Factors include valuation, momentum, quality, and risk control metrics - Stocks are selected based on their scores across these factors, aiming to optimize the portfolio for enhanced returns while maintaining alignment with the CSI 300 Index [60] - **Factor Evaluation**: The multi-factor approach has been effective in generating consistent excess returns and controlling risks [60] --- Factor Backtesting Results 1. Multi-Factor Stock Selection - **Excess Returns**: Contributed to the fund's annualized excess return of 6.49% since inception [42][43] - **Risk Control**: Supported low tracking error (average 2.68% annually) and controlled maximum drawdowns [44][45]

2025 年 07 月 11 日 煤炭 稳中求胜，红利为锚 年初至 630 煤炭板块涨跌幅-12%，位居行业最末：2025 年上半 年，由于国内供应端以能源保供作为生产目标的方向并未发生改 变，供应充足与下游补库积极性放缓相互叠加使得价格持续缺乏 向上动能，秦港 Q5500 动力煤平仓价从年初的 765 元/吨下跌 150 元/吨至 615 元/吨，持续处于中长期合同合理区间之内，且 3 月 下旬以来持续低于中长期合同价格；2025H1 均价为 678 元/吨， 同比-23%。京唐港主焦煤从年初的 1520 元/吨下跌 290 元/吨至 1230 元/吨，当前位于近五年来最低点；2025H1 均价 1383 元/吨， 同比-39%。现货价格的持续下跌引发投资者对于板块业绩稳定性 的质疑，叠加市场对于煤炭基本面继续供需宽松的一致预期使得 股价持续承压，截至 6 月 30 日，煤炭板块（申万）涨跌幅-12.29%， 跑输沪深 300，并位居申万行业跌幅最末。细分板块看，动力煤 （申万）涨跌幅-10.11% ，焦煤（申万）涨跌幅-19.04%。 迎峰度夏高温来袭，关注三季度电煤需求向上弹性：1）供给： 内产方面，国 ...

2025 年 07 月 10 日 沪电股份(002463.SZ) 受益 AI 新兴需求，上半年业绩大幅增 长 事件： 公司发布 2025 年半年度业绩预告，上半年归母净利润 165,000 万元 –175,000 万元，比上年同期增长 44.63% - 53.40%。扣非后净利润 161,000 万元-171,000 万元，比上年同期增长 44.85% - 53.85%。 深耕高端 PCB 客户，业绩大幅增长： | | PCB | | --- | --- | | 投资评级 | 买入-A | | | 维持评级 | | 6 个月目标价 | 58.21 元 | | 股价 (2025-07-10) | 47.25 元 | | 交易数据 | | | 总市值(百万元) | 90,880.11 | | 流通市值(百万元) | 90,821.20 | | 总股本(百万股) | 1,923.39 | | 流通股本(百万股) | 1,922.14 | 12 个月价格区间 24.94/49.07 元 股价表现 资料来源：Wind 资讯 升幅% 1M 3M 12M 相对收益 24.4 66.0 -2.4 绝对收益 28.2 73.4 ...